Loading…
China SXT Pharmaceuticals, Inc. is projected to decline to $0.0663 by 2027, a -14% move from its current price of $0.0769. SXTC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.0675 | $0.0769 | $0.0876 | -0.01% |
| Aug 6 | $0.0639 | $0.0769 | $0.0925 | -0.03% |
| Aug 7 | $0.0613 | $0.0769 | $0.0964 | -0.04% |
| Aug 8 | $0.0592 | $0.0769 | $0.0998 | -0.06% |
| Aug 9 | $0.0574 | $0.0768 | $0.103 | -0.07% |
| Aug 10 | $0.0558 | $0.0768 | $0.1059 | -0.08% |
| Aug 11 | $0.0543 | $0.0768 | $0.1086 | -0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.0543 | $0.0768 | $0.1086 | -0.10% |
| Week 2 | $0.047 | $0.0768 | $0.1252 | -0.19% |
| Week 3 | $0.0421 | $0.0767 | $0.1397 | -0.29% |
| Week 4 | $0.0383 | $0.0766 | $0.1531 | -0.39% |
| Week 5 | $0.0353 | $0.0765 | $0.166 | -0.49% |
| Week 6 | $0.0327 | $0.0765 | $0.1785 | -0.58% |
| Week 7 | $0.0306 | $0.0764 | $0.1909 | -0.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
China SXT Pharmaceuticals, Inc. is a healthcare company that engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. It offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal materials, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. It serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc.
was incorporated in 2005 and is headquartered in Taizhou, China.
SXTC is a healthcare stock with a current price of $0.0618 and a modest market capitalization of $2.36M, ranking 5420. The stock’s price action is framed by a neutral near-term stance, with a modest market position that suggests limited liquidity. The forecast for 2026 shows an average price of $0.0618, with a neutral sentiment, illustrating a flat near-term path.
Looking further ahead, the forecast presents a path of mixed but progressively stronger upside, culminating in bullish milestones in 2033, 2040, and 2050 with notable ROIs.
A major floor 31.1% below — a decisive break under it would weaken the trend.
The nearest floor, 31.1% below — buyers have tended to step in here.
The nearest ceiling, 3385.0% above — a clean break opens room to run.
A major ceiling 4527.7% above — clearing it would confirm fresh momentum.
Key SXTC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SXTC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.0632 | Buy | $0.2064 | Sell |
| MA 10 | $0.7843 | Sell | $0.6568 | Sell |
| MA 20 | $1.64 | Sell | $1.23 | Sell |
| MA 50 | $1.85 | Sell | $2.56 | Sell |
| MA 100 | $1.84 | Sell | $15.93 | Sell |
| MA 200 | $67.31 | Sell | $59.69 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 21.08 | Buy |
| Stoch RSI (14) | 1.28 | Buy |
| CCI (20) | -97.70 | Neutral |
| Williams %R (14) | -99.66 | Info |
| MACD (12,26,9) | -0.24 | Sell |
| ROC (12) | -97.60 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 0.34 | Buy |
| TRIX (15) | -2.14 | Sell |
| Awesome (5,34) | -1.87 | Sell |
| Ultimate (7,14,28) | 8.24 | Buy |
| Momentum (10) | -2.39 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | -0.22 | Buy |
| ADX (14) | 34.02 | Sell |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is labeled NEUTRAL, with an RSI of 20. The 50-day simple moving average is $1.85, and the 200-day moving average is $67.31. Immediate support sits at $0.053 and resistance at $2.68, framing a wide range for short-term movement.
The 30-day range for SXTC spans from a low of $0.0185 to a high of $0.2061, indicating substantial volatility within a narrow price band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.053 | $0.0769 | $0.0929 | 0% | Neutral | |
| $0.0483 | $0.0663 | $0.0983 | -14% | Neutral | |
| $0.0452 | $0.0659 | $0.1044 | -14% | Neutral | |
| $0.0351 | $0.054 | $0.0898 | -30% | Bearish | |
| $0.044 | $0.0709 | $0.1228 | -8% | Neutral | |
| $0.0511 | $0.0862 | $0.1545 | +12% | Neutral | |
| $0.0491 | $0.0863 | $0.1597 | +12% | Neutral | |
| $0.0517 | $0.0948 | $0.1801 | +23% | Bullish | |
| $0.0416 | $0.0792 | $0.1543 | +3% | Neutral | |
| $0.0345 | $0.0683 | $0.1363 | -11% | Neutral | |
| $0.0501 | $0.1114 | $0.2443 | +45% | Bullish | |
| $0.0874 | $0.1941 | $0.4465 | +152% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.053 | $0.0769 | $0.0913 | +0.00% |
| September 2026 | $0.0595 | $0.0723 | $0.0917 | -5.98% |
| October 2026 | $0.0616 | $0.0759 | $0.0983 | +5.02% |
| November 2026 | $0.0604 | $0.0752 | $0.099 | -0.90% |
| December 2026 | $0.0553 | $0.0696 | $0.0929 | -7.45% |
Click any year to see its month-by-month SXTC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
China SXT Pharmaceuticals, Inc.'s 2026 outlook centres on $0.0769, within a $0.053 to $0.0929 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SXTC could reach as high as $0.0983, with a base case around $0.0663 and support toward $0.0483 — roughly -14% from $0.0769. Price action looks broadly range-bound.
Expect SXTC to range from $0.0452 to $0.1044 through 2028. The $0.0659 average target implies a -14% move from current prices. That is 0% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The SXTC price prediction for 2029 points to an average of $0.054 (low $0.0351, high $0.0898) — a potential decline of -30% on today's $0.0769. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2030, SXTC is projected to trade between $0.044 and $0.1228, averaging $0.0709 — a potential decline of -8% from today's $0.0769. That is up +31% on the projected 2029 average. A consolidation phase looks the most probable path here.
China SXT Pharmaceuticals, Inc.'s 2031 outlook centres on $0.0862, within a $0.0511 to $0.1545 range. That is up +22% on the projected 2030 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2032, SXTC could reach as high as $0.1597, with a base case around $0.0863 and support toward $0.0491 — roughly +12% from $0.0769. A consolidation phase looks the most probable path here.
Expect SXTC to range from $0.0517 to $0.1801 through 2033. The $0.0948 average target implies a +23% move from current prices. That is up +10% on the projected 2032 average. Momentum favours further upside here.
The SXTC price prediction for 2034 points to an average of $0.0792 (low $0.0416, high $0.1543) — a potential gain of +3% on today's $0.0769. A consolidation phase looks the most probable path here.
In 2035, SXTC is projected to trade between $0.0345 and $0.1363, averaging $0.0683 — a potential decline of -11% from today's $0.0769. That is -14% versus the projected 2034 average. Price action looks broadly range-bound.
China SXT Pharmaceuticals, Inc.'s 2040 outlook centres on $0.1114, within a $0.0501 to $0.2443 range. That is up +63% on the projected 2035 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SXTC could reach as high as $0.4465, with a base case around $0.1941 and support toward $0.0874 — roughly +152% from $0.0769. Momentum favours further upside here.
Investing $1,000 in SXTC today (≈ 13,003.90117 SXTC) could be worth
$2,524.45
+$1,524.45 (+152%) by 2050 · US Dollar
Based on the average projected SXTC price of $0.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SXTCwould be worth at today's price.
$1,000 invested in SXTC on Jul 31, 2025 (≈ 4.273504 SXTC) would be worth
$0.33
-$999.67 (-100.0%) today · 0.00× · US Dollar
Based on a SXTC entry price of $234 vs. today's $0.0769.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.064 | $1,201.56 | +20.2% |
| 1 month ago | $2.46 | $31.26 | -96.9% |
| 3 months ago | $2.07 | $37.15 | -96.3% |
| 6 months ago | $6.45 | $11.92 | -98.8% |
| 1 year ago | $234 | $0.33 | -100.0% |
| All time (5.0y) ago | $4,687.5 | $0.02 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SXTC forecast.
Our base-case forecast reaches $0.15 around 2050.
Implied market cap at $0.15: $5.73M
The multi-year forecast shows a cautious start, with 2030 at an average of $0.0571 and a negative ROI of -7.7%, followed by 2031 at $0.0693 with a 12.1% ROI and 2032 at $0.0693 with a 12.2% ROI. The 2033 forecast turns more positive, at an average of $0.0763 and a 23.5% ROI, before 2034 softening to $0.0634 with a 2.7% ROI and 2035 at $0.0547 with an -11.5% ROI. The outlook improves significantly by 2040, with an average of $0.0893 and a 44.5% ROI, and again in 2050, with an average of $0.1559 and a 152.3% ROI.
The sentiment turns bullish in 2033, 2040, and 2050, reflecting a longer-run upgrade despite earlier cycles of weakness. Investors should note that the forecast includes years with negative ROIs, underscoring uncertainty and risk along the path to later gains.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.0571, with a range from $0.0354 to $0.0988 and a ROI of -7.7%. The sentiment is NEUTRAL.
The forecast contains years of both negative and positive returns. Notably, 2031 and 2032 show ROIs of 12.1% and 12.2%, 2033 shows 23.5%, 2040 shows 44.5%, and 2050 shows 152.3% positive ROI, while years like 2029 and 2035 show negative ROIs (-30% and -11.5%). This indicates potential upside in the longer term but carries substantial downside risk in earlier years.
No. The forecasted maximums are $0.0988 (2030), $0.1242 (2031), $0.1282 (2032), $0.145 (2033), $0.1959 (2040), and $0.3586 (2050), with none reaching $0.50.
The current price is $0.0618 and the market cap is $2.36M.
The 30-day range is from $0.0185 to $0.2061.
China SXT Pharmaceuticals, Inc. Community Discussion
0Share your China SXT Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.